When BSC was the control arm (the ‘later line’ trials), EGFR mAb therapy provided OS and PFS benefit in patients with KRAS WT cancers (OS HRadj 0.79, p = 0.036 and PFS HRadj 0.41, p < 0.001). This evidence concerns the gene KRAS and cancer.